Premium
Human cord blood CD133+ cells immunoselected by a clinical‐grade apparatus differentiate in vitro into endothelial‐ and cardiomyocyte‐like cells
Author(s) -
Bonanno Giuseppina,
Mariotti Andrea,
Procoli Annabella,
Corallo Maria,
Rutella Sergio,
Pessina Gloria,
Scambia Giovanni,
Mancuso Salvatore,
Pierelli Luca
Publication year - 2007
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2007.01104.x
Subject(s) - endothelial stem cell , umbilical vein , umbilical cord , stem cell , endothelium , in vitro , medicine , immunology , microbiology and biotechnology , pathology , andrology , biology , biochemistry
BACKGROUND: Recent findings on human hematopoietic stem cell (HSC) properties suggest a possible therapeutic role of human umbilical cord blood (UCB) HSC‐based cellular therapies in the treatment of myocardial infarction. STUDY DESIGN AND METHODS: Nine UCB units were subjected to sequential red cell removal, freezing, and postthawing CD133+ HSC immunoselection by a clinical‐grade, CE‐approved, magnetic apparatus and microbead‐coated anti‐CD133 monoclonal antibody. Selected UCB CD133+ cells were cultured in vitro in medium supporting either endothelial or cardiomyocytic differentiation in parallel experiments. RESULTS: Immunoselection allowed recovery of 79 percent of initial CD133+ cells with a CD133+ cell purity of 81 percent, on average. Parallel cultures showed the appearance of endothelial markers (VE‐cadherin, CD146, and KDR and bright expression of CD105), morphofunctional features of endothelium in endothelial‐supporting cultures, of cardiac muscle proteins (troponin I and myosin ventricular heavy chain α/β; MYHC) and specific gene expression (GATA4, NKX2.5, troponin I, and MYHC) in cardiomyocyte‐oriented cultures. CONCLUSIONS: The appearance of both endothelial‐ and cardiomyocyte‐like cells from parallel cultures of frozen‐thawed‐immunoselected UCB CD133+ cells by a clinical‐grade method and previously reported data on lack of major signs of rejection of these cells in immunocompetent rats subjected to experimental liver damage suggest a possible role of these allogeneic HSCs in cell therapies designed for regenerative treatments of ischemic diseases of human myocardium.